FIELD: chemistry.
SUBSTANCE: invention relates to a compound of formula I or a pharmaceutically acceptable salt thereof, where R1 is hydrogen or (C1-C10)alkyl group; R2 is H, halogen, COOH, (C1-C6)alkyl, optionally substituted with -NR10R11, OH or (C1-C4)alkoxy, optionally substituted OH; (C1-C6)alkoxy, optionally substituted OH, (C1-C4)alkoxy or group -NR12R13; group of -OR14, where R14 denotes a 5- or 6-member heterocycloalkyl, containing 1 or 2 nitrogen atoms; group -CONR15R16, where R15 and R16 each independently denotes H or (C1-C4)alkyl, optionally substituted (C1-C4)alkoxy or 5- or 6-member heterocycloalkyl, containing 1 or 2 heteroatoms selected from O and N; group -NR17R18, where R17 denotes H or (C1-C4)alkyl and R18 denotes H, (C1-C4)alkyl, optionally substituted with (C1-C4)alkoxy, or 5- or 6-member heteroaryl containing 1–3 heteroatoms selected from O, S and N; group -NR19COR20, where R19 denotes H and R20 denotes (C1-C4)alkyl, optionally substituted amino, (C1-C4)alkylamino or di(C1-C4)alkylamino or 5- or 6-member heterocycloalkyl, containing 1 or 2 nitrogen atoms, said heterocycloalkyl is optionally substituted with 1–3 (C1-C4)alkyls; or 5- or 6-member heterocycloalkyl or heteroaryl containing 1 or 2 nitrogen atoms, said heterocycloalkyl or heteroaryl is optionally substituted with oxo groups; R3 is hydrogen, halogen, cyano, (C1-C10)alkyl group or (C1-C10)alkoxy group, CF3; Q denotes O or S; W is N or CR21; X is N or CR25, where R25 is H; CN; (C1-C4)alkyl; or group -COO(C1-C4)alkyl; and A denotes a 5- or 6-member heterocycloalkyl or heteroaryl containing 1–3 nitrogen atoms, said heterocycloalkyl or heteroaryl is optionally substituted with 1–3 substitutes, selected from an oxo group; halogen; (C1-C4)alkyl, optionally substituted amino, (C1-C4)alkylamino, di(C1-C4)alkylamino or 5- or 6-member heterocycloalkyl, containing 1 or 2 nitrogen atoms. Invention also relates to a pharmaceutical composition for treating a disease mediated by inhibition of native and/or mutant c-kit, containing a compound of formula I or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier.
EFFECT: selective inhibitors of native and/or mutant protein kinase c-kit.
10 cl, 3 tbl, 225 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUND OF FORMULA (I), PHARMACEUTICAL COMPOSITION, APPLICATION OF COMPOUND OF FORMULA (I) FOR TREATMENT OF HEMATOLOGICAL AND/OR PROLIFERATIVE DISORDERS | 2016 |
|
RU2758259C2 |
| ARYL-N-ARYL DERIVATIVES FOR TREATING RNA VIRAL INFECTION | 2020 |
|
RU2821414C2 |
| SUBSTITUTED BENZENE COMPOUNDS | 2013 |
|
RU2658919C2 |
| CONTAINING A SUBSTITUTE, WHICH IS BUTANE, IN THE HETEROCYCLIC RING A PYRIDONE DERIVATIVE FOR TREATING FIBROSIS AND INFLAMMATORY DISEASES | 2017 |
|
RU2738844C2 |
| 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND VARIANTS OF THEIR USE | 2018 |
|
RU2795850C2 |
| DERIVATIVES OF NOR-SECO-CHIMBACINE, PHARMACEUTICAL COMPOSITION AND METHOD FOR INHIBITING BASED ON THEREOF | 2001 |
|
RU2293735C2 |
| HETEROCYCLIC INHIBITORS OF MCT4 | 2017 |
|
RU2771875C2 |
| CONDENSED TRICYCLIC BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2689777C1 |
| COMPOUNDS AND COMPOSITIONS AS ITPKb INHIBITORS | 2007 |
|
RU2425826C2 |
| DIARYL COMPOUNDS WITH BRIDGE BOND | 2002 |
|
RU2297409C2 |
